NCT02355535已完成1 期
(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 3
- 主要终点
- Maximum Tolerated Dose
研究概览
简要总结
This Phase I dose escalation study will evaluate Procaspase Activating Compound-1 (PAC-1), a small molecule that activates procaspase -3 to caspase-3, resulting in apoptosis of cancer cells, in patients with advanced malignancies. As of March 1, 2019, only patients with neuroendocrine tumors will be enrolled in Component 1 of this study. PAC-1 is taken orally on days 1-21 of a 28-day cycle. The maximum tolerated dose (MTD) of PAC-1 (5 dose levels) will be determined using a modified-Fibonacci dose-escalation 3+3 design. Treatment continues until disease progression, unacceptable toxicity, physician discretion, or patient refusal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥ 18 years of age
- •Diagnosis of advanced solid tumor or hematologic malignancy (limited to lymphoma) that has failed or become intolerant to standard therapy
- •Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1, or lymphoma that fulfills the Deauville PET Criteria
- •Has an ECOG PS of 0, 1, or 2
- •Has total bilirubin < 1.5 mg/dL, serum albumin > 3.0 gm/dL, AST and ALT < 1.5 ULN or < 3 x ULN for subjects with known hepatic metastases
- •Has serum creatinine < 1.5 × ULN
- •Has hemoglobin ≥ 10 g/dL, ANC ≥ 1.5 × 109/L, and platelet count ≥ 100 × 109/L
- •Must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after capsule(s) administration
- •Must be willing and able to comply with study
- •Has read, understood, and signed the ICF
- •Women of childbearing potential must not be pregnant or breast-feeding. In addition, a medically acceptable method of birth control must be used or total abstinence. Women who are postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered to be WOCP
- •Men who are not surgically or medically sterile must agree to use an acceptable method of contraception. Male patients with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant during the study must agree to use condoms at least one month after the last dose of study drug. Total abstinence for the same study period is an acceptable alternative
- •Prior systemic treatments for metastatic disease are permitted but may not be ongoing, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy
- •Willingness to donate blood for biomarker studies related to the type of therapies used in this trial and the tumor types being treated
排除标准
- •Had surgery within 4 weeks prior to study treatment except for minor procedures (hepatic biliary stent placement is allowed)
- •Gliomas are excluded, as well as any history of brain metastases, seizures or underlying brain injury
- •May not have received cytotoxic chemotherapy, targeted therapies, biologic response modifiers, chemotherapy, and hormonal therapy within the last 3 weeks, or nitrosureas within the last 6 weeks prior to study treatment.
- •Has a history of blood clots, pulmonary embolism, or DVT unless controlled by anticoagulant treatment
- •Has a history of an arterial thromboembolic event within the prior six months including CVA, TIA, MI, or unstable angina
- •Has uncontrolled HIV or hepatitis B or C
- •Has any clinically significant infection
- •Has any other severe, uncontrolled medical condition, including uncontrolled DM or unstable CHF
- •Radiation therapy to more than 25% of the bone marrow
- •Prior allogeneic bone marrow or organ transplantation
- •> Grade 1 peripheral neuropathy within 14 days before enrollment.
- •Patient has received other investigational drugs with 14 days before enrollment
- •Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation
- •Abnormalities on 12-lead electrocardiogram (ECG) considered by the investigator to be clinically significant (such as acute ischemia, left bundle branch block, ventricular arrhythmias) or baseline prolongation of the rate-corrected QT interval (e.g., repeated demonstration of QTc interval > 480 milliseconds)
- •Presence of any non-healing wound, fracture, or ulcer
- •Has any condition that, in the opinion of the investigator, might jeopardize the safety of the patient or interfere with protocol compliance
- •Has any mental or medical condition that prevents the patient from giving informed consent
研究组 & 干预措施
Open label
Experimental
Using a dose-escalation design, PAC-1 is administered orally on days 1-21, at the assigned dose, of a 28-day cycle.
干预措施: PAC-1 (Drug)
结局指标
主要结局
Maximum Tolerated Dose
时间窗: Up to 30 days post last dose
The primary objective of this study component is to determine the maximum tolerated dose (MTD) of PAC-1 in patients with advanced, previously treated malignancy, by evaluation of toxicity and tolerability.
次要结局
- Adverse Effects(Up to 30 days post final dose)
- Disease Response based on Deauville PET Criteria for patients with lymphoma(Up to 8 weeks following final dose)
- Disease Response based on RECIST Criteria for patients with solid tumors(Up to 8 weeks following final dose)
研究者
Oana Danciu, MD
Assistant Professor
University of Illinois at Chicago
研究点 (3)
Loading locations...
相似试验
终止
1 期
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2Anaplastic AstrocytomaGlioblastoma MultiformeNCT03332355Vanquish Oncology, Inc.18
已完成
1 期
PSA-Activated PSA-PAH1 for Locally Recurrent Prostate CancerProstate CancerNCT00379561Sophiris Bio Corp24
已完成
1 期
Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid MalignancySolid TumorMetastatic CancerNCT02412462Alethia Biotherapeutics15
已完成
不适用
Effect of a Proposed Cav1.3 Inhibitor in Primary AldosteronismEndocrine HypertensionPrimary AldosteronismNCT05686993Queen Mary University of London15
Unknown
1 期
Study of Safety and Biomarker Efficacy of TS23 in Healthy VolunteerThrombosisCerebral IschemiaMyocardial InfarctionVenous ThrombosisPulmonary EmbolismNCT03001544Translational Sciences, Inc.24